INKT
MiNK Therapeutics, Inc.Company Information
- Company Name
- MiNK Therapeutics, Inc.
- CIK
- CIK0001840229
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- INKT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- INKT
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-10-16
- Last sale
- 2026-06-04
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 2,900
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 204,327
- Shares outstanding
- 5,023,450
- Ownership
- 4.07%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 5.82%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 9 | 10 | 13 | 14 | 2 | 3 | 5 | 6 | 9 | 6 | 3 | 6 | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 9 | 10 | 14 | 15 | 2 | 4 | 5 | 7 | 9 | 6 | 4 | 6 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 10 | 10 | 14 | 15 | 2 | 4 | 6 | 7 | 10 | 7 | 5 | 7 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 4 | 3 | 3 | 4 | 3 | 3 | 3 | 2 | 3 | 3 | 4 | 4 | ||||||
| Accrued Liabilities Current | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 3 | 5 | 5 | 5 | 4 | ||||||
| Other Liabilities Current | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Current | 8 | 7 | 13 | 13 | 13 | 12 | 7 | 7 | 10 | 11 | 11 | 10 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 149 | 147 | 143 | 141 | 127 | 126 | 125 | 125 | 124 | 117 | 116 | 115 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -163 | -159 | -157 | -154 | -151 | -147 | -144 | -142 | -140 | -137 | -133 | -128 | ||||||
| Stockholders Equity | -14 | -13 | -14 | -14 | -25 | -22 | -20 | -18 | -17 | -20 | -18 | -14 | ||||||
| Liabilities And Stockholders Equity | 10 | 10 | 14 | 15 | 2 | 4 | 6 | 7 | 10 | 7 | 5 | 7 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | ||||||
| Shares Outstanding | 5 | - | - | - | - | - | 4 | - | - | - | 3 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMiNK Therapeutics, Inc. (INKT) — SEC Financial Statements & Analysis
MiNK Therapeutics, Inc. (INKT) is a biological products, (no diagnostic substances) company, incorporated in DE. MiNK Therapeutics, Inc. trades on Nasdaq as: INKT. MiNK Therapeutics, Inc. (INKT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, MiNK Therapeutics, Inc. carries a market cap of $58.72M, a P/E ratio of -5.17x, a P/B ratio of -4.19x, an enterprise value of $49.92M, and an EV/EBITDA multiple of -4.22x. On profitability, it posts a Return on Equity (ROE) of 57.94% and a Return on Assets (ROA) of -187.78%. Per share, it reports EPS of $-2.26, diluted EPS of $-2.26, free cash flow per share of $-1.36, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 0.76% year-over-year and EPS growth of -20.13% year-over-year. On the balance sheet, it maintains a current ratio of 1.23x, a quick ratio of 1.19x, working capital of $1.73M, a debt-to-equity ratio of -0.54x, a debt ratio of 0.79, an interest coverage ratio of -37.45x, free cash flow of $-6.83M (TTM), and net debt of $-8.81M. Figures sourced from SEC EDGAR.
- Market Cap
- $58.72M
- P/E TTM
- -5.17x
- EPS TTM
- $-2.26
- P/B TTM
- -4.19x
- ROE TTM
- 57.94%
- ROA TTM
- -187.78%
- Debt To Equity
- -0.54x
- Free Cash Flow TTM
- $-6.83M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is MiNK Therapeutics, Inc. in?
MiNK Therapeutics, Inc. (INKT) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does INKT trade on?
MiNK Therapeutics, Inc. (INKT) trades on the Nasdaq.
Where is MiNK Therapeutics, Inc. incorporated?
MiNK Therapeutics, Inc. is incorporated in DE.
When was MiNK Therapeutics, Inc. (INKT)'s most recent SEC filing?
MiNK Therapeutics, Inc. (INKT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is INKT's market cap?
MiNK Therapeutics, Inc. (INKT) has a market capitalization of $58.72M as of 2026-06-30.
What is INKT's EPS (earnings per share)?
MiNK Therapeutics, Inc. (INKT)'s trailing twelve month EPS is $-2.26 as of 2026-06-30.
What is INKT's ROE (return on equity)?
MiNK Therapeutics, Inc. (INKT)'s trailing twelve month Return on Equity (ROE) is 57.94% as of 2026-06-30.
What is INKT's ROA (return on assets)?
MiNK Therapeutics, Inc. (INKT)'s trailing twelve month Return on Assets (ROA) is -187.78% as of 2026-06-30.
What is INKT's EV/EBITDA?
MiNK Therapeutics, Inc. (INKT)'s trailing twelve month EV/EBITDA is -4.22x as of 2026-06-30.